Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

Breast Neoplasm Female Clinical Trial

Official title:

Peking University Cancer Hospital & Institute

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05577442
• Other study ID #: OBU-BC-?-077
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: October 20, 2022
• Est. completion date: October 20, 2024

Study information

• Verified date: October 2022
• Source: Peking University Cancer Hospital & Institute
• Contact: GUOHONG SONG
• Phone: 13911263305
• Email: songguohong918[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study investigates the efficacy and safety of trastuzumab, pyrotinib combined with dalpiciclib and endocrine therapy for patients with advanced HR+/HER2+ brest cancer, providing more possible effective regimens for the survival benefit of these patients in clinical practice.

Description:

This study is a single-arm, open-label, multicenter, phase II clinical study. Subjects were eligible for screening and entered the trial period after enrollment and received treatment with pyrotinib（320mg/day), trastuzumab(8 mg→6mg/every 3 week), dalpiciclib(125mg once daily for 3 weeks, followed by 1 week off in each 4-week cycle), endocrine therapy until disease progression, or intolerable toxicity, or withdrawal of informed consent, or discontinuation of medication at the investigator 's discretion. On-study imaging assessments were performed according to RECIST 1.1 criteria and the site assessment was final.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 52
• Est. completion date: October 20, 2024
• Est. primary completion date: October 20, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Female breast cancer patients of any menopausal status aged 18-75 years.

2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.

3. Female breast cancer patients with HER2-positive HR-positive of recurrence or metastasis and are not suitable for surgical resection or radiation therapy with the purpose of cure.

4. ER and/or PR +: defined as positively stained tumor cells representing = 10% of all tumor cells (confirmed by investigator review at the site) and HER2 +: defined as IHC 3 + or IHC 2 + and FISH +/CISH +.

5. measurable lesions by RECIST 1.1 criteria.

6. Patients' previous treatment should meet: a) prior systemic (neo) adjuvant therapy is allowed but not required, and if received, the disease-free interval (DFI) must be > 24 months (DFI is defined as the time from surgery to the first recurrence); b) = 1 line of systemic therapy for the tumor (including anti-HER2 targeted therapy, endocrine therapy and chemotherapy) is received at the metastatic stage;

7. Stable patients with brain metastases are allowed.

8. life expectancy = 12 weeks.

9. adequate organ and bone marrow function.

10. adequate cardiac reserve, left ventricular ejection fraction (LVEF) = 45% on echocardiogram.

Exclusion Criteria:

1. patients who are not suitable for endocrine therapy as judged by the investigator. Including symptomatic, advanced patients with disseminated visceral disease who are at short-term risk of life-threatening complications (including patients with uncontrolled large exudates [pleural, pericardial, abdominal], pulmonary lymphangitis and more than 50% hepatic involvement).

2. previous treatment with CDK4/6 inhibitors.

3. previous treatment with TKI.

4. visceral crisis.

5. Major surgery, chemotherapy, radiation therapy, any investigational agent, or other anticancer therapy within 2 weeks before entering the study.

6. Have been diagnosed with any other malignancy within 3 years before entering the study, except for curatively treated non-melanoma skin cancer, basal cell or squamous cell skin cancer, or cervical carcinoma in situ.

Related Conditions & MeSH terms

• Breast Neoplasm Female
• Breast Neoplasms

Intervention

Drug:
• Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy
Trastuzumab (8-6mg/3weekly),Pyrotinib(320mg/day)Dalpiciclib(125mg/day,With three weeks separated by one week)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Peking University Cancer Hospital & Institute

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ORR		8week